MedPath

Levothyroxine

Generic Name
Levothyroxine
Brand Names
Eltroxin, Ermeza, Euthyrox, Levo-T, Levothroid, Levoxyl, Np Thyroid, Synthroid, Thyquidity, Tirosint, Unithroid
Drug Type
Small Molecule
Chemical Formula
C15H11I4NO4
CAS Number
51-48-9
Unique Ingredient Identifier
Q51BO43MG4
Background

Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quantities of the thyroid hormones T (tetraiodothyronine or thyroxine) and T (triiodothyronine or Liothyronine), resulting in diminished down-stream effects of these hormones. Without sufficient quantities of circulating thyroid hormones, symptoms of hypothyroidism begin to develop such as fatigue, increased heart rate, depression, dry skin and hair, muscle cramps, constipation, weight gain, memory impairment, and poor tolerance to cold temperatures.

In response to Thyroid Stimulating Hormone (TSH) release by the pituitary gland, a normally functioning thyroid gland will produce and secrete T, which is then converted through deiodination (by type I or type II 5′-deiodinases) into its active metabolite T. While T is the major product secreted by the thyroid gland, T exerts the majority of the physiological effects of the thyroid hormones; T and T have a relative potency of ~1:4 (T4:T3). T and T act on nearly every cell of the body, but have a particularly strong effect on the cardiac system. As a result, many cardiac functions including heart rate, cardiac output, and systemic vascular resistance are closely linked to thyroid status.

Prior to the development of levothyroxine, Thyroid, porcine or desiccated thyroid, used to be the mainstay of treatment for hypothyroidism. However, this is no longer recommended for the majority of patients due to several clinical concerns including limited controlled trials supporting its use. Desiccated thyroid products contain a ratio of T4 to T3 of 4.2:1, which is significantly lower than the 14:1 ratio of secretion by the human thyroid gland. This higher proportion of T3 in desiccated thyroid products can lead to supraphysiologic levels of T3 which may put patients at risk of thyrotoxicosis if thyroid extract therapy is not adjusted according to the serum TSH.

Indication

Levothyroxine is indicated as replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. It is also indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.

Associated Conditions
Edematous Fibrosclerotic Panniculopathy (Cellulite), Hypothyroidism, Localized Adiposity, Myxedema coma, Euthyroid Goitre, Thyrotropin dependent Well-Differentiated Thyroid Cancer

Necessity of TSH Suppression Therapy in Active Surveillance for Thyroid Cancer Patients.

Not Applicable
Not yet recruiting
Conditions
Thyroid Cancer
Papillary Thyroid Carcinoma
Interventions
First Posted Date
2025-05-14
Last Posted Date
2025-05-14
Lead Sponsor
National Cancer Center, Korea
Target Recruit Count
578
Registration Number
NCT06971965

Novel Approaches to the Treatment of Hypothyroidism

Phase 2
Recruiting
Conditions
Hypothyroidism
Interventions
Drug: Levothyroxine/Liothyronine twice daily
Drug: Levothyroxine/Liothyronine once daily
First Posted Date
2024-12-12
Last Posted Date
2025-03-30
Lead Sponsor
UConn Health
Target Recruit Count
90
Registration Number
NCT06731764
Locations
🇺🇸

UConn Health, Farmington, Connecticut, United States

Role of Levothyroxine Supplementation in Delayed Recovery Following Cardiac Surgery

Phase 3
Recruiting
Conditions
Cardiac Surgery Intensive Care Treatment
Delayed Recovery From Anaesthesia
Euthyroid Sick Syndrome
Cardiac Surgery Requiring Cardiopulmonary Bypass
Interventions
Drug: Placebo Oral Tablet
First Posted Date
2024-10-28
Last Posted Date
2025-05-06
Lead Sponsor
Ain Shams University
Target Recruit Count
50
Registration Number
NCT06660823
Locations
🇪🇬

Faculty of Medicine ,Ain Shams University, Cairo, Egypt

Effect of HCQ Combined With LT4 on LBR in Euthyroid Women With URPL and TPO-Ab

Not Applicable
Not yet recruiting
Conditions
Recurrent Pregnancy Loss
Euthyroid With Thyroid Antibodies
Interventions
First Posted Date
2024-10-22
Last Posted Date
2024-10-22
Lead Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Target Recruit Count
796
Registration Number
NCT06652113
Locations
🇨🇳

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China

Levothyroxine Intervention in Pregnant Women with TSH (2.5 MIU/L-upper Limit of Reference Range) and Negative Thyroid Peroxidase Antibody

Phase 4
Not yet recruiting
Conditions
Thyroid Abnormalities
Pregnant Woman
Pregnancy Outcomes
Interventions
First Posted Date
2024-10-22
Last Posted Date
2024-10-23
Lead Sponsor
Yang ZHANG
Target Recruit Count
400
Registration Number
NCT06653907
Locations
🇨🇳

Fourth hospital of Shijiazhuang city, Shijiazhuang, Heibei, China

Thyroid Hormone for Thyroid Cancer

Not yet recruiting
Conditions
Differentiated Thyroid Cancer
Thyroid Cancer
Levothyroxine
Liothyronine
Thyroid Hormones
Interventions
First Posted Date
2024-10-18
Last Posted Date
2024-10-18
Lead Sponsor
University Medical Center Groningen
Target Recruit Count
40
Registration Number
NCT06647602
Locations
🇳🇱

University Medical Center Groningen (UMCG), Groningen, Netherlands

🇳🇱

Radboud University Nijmegen, Nijmegen, Netherlands

A Study of Levothyroxine and Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-028)

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2024-10-03
Last Posted Date
2024-10-03
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
28
Registration Number
NCT06625814
Locations
🇺🇸

Celerion (Site 0001), Lincoln, Nebraska, United States

Levothyroxine-sodium Bioequivalence Trial With Oral Single Dose Administration

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2024-08-09
Last Posted Date
2024-08-09
Lead Sponsor
Berlin-Chemie AG Menarini Group
Target Recruit Count
132
Registration Number
NCT06547242
Locations
🇩🇪

Phase I Unit, Erfurt, Thuringia, Germany

Correlation Between Levothyroxine and Blood Th17/Treg in Pregnant Women With Normal-high TSH and Positive TPOAb

Terminated
Conditions
Thyroid Stimulating; Hormone, C
Pregnancy Related
Interventions
First Posted Date
2024-07-30
Last Posted Date
2024-07-30
Lead Sponsor
Third Affiliated Hospital of Zhengzhou University
Target Recruit Count
64
Registration Number
NCT06527859
Locations
🇨🇳

The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

Levothyroxine Supplementation for Heart Transplant Recipients

Phase 1
Recruiting
Conditions
Heart Transplant Failure
Heart Transplant Infection
Interventions
Drug: Normal saline
First Posted Date
2024-05-24
Last Posted Date
2025-05-01
Lead Sponsor
University of California, San Francisco
Target Recruit Count
97
Registration Number
NCT06428097
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

© Copyright 2025. All Rights Reserved by MedPath